ScreenerHero

CPIX Cumberland Pharmaceuticals Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · cumberlandpharma.com
6.655USD-3.41%Mkt Cap: 103.23M $P/E: —

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment o…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.13BUSDP/E 24.9
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.68BUSDP/E 22.9
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap103.23M USD
Enterprise Value107.50M USD
Revenue (TTM)44.30M USD
Gross Profit37.85M USD
Net Income (TTM)-2.84M USD
Revenue/Share2.98 USD
Last Price6.655 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees88
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)51.00
PEG1.67
EV/EBITDA98.02
EV/Revenue2.43
P/S2.41
P/B6.13
EPS (TTM)-0.62
EPS (Forward)0.14
52W Range
1.85065% of range9.280
52W High9.280 USD
52W Low1.850 USD
Profitability
Gross Margin85.02%
Oper. Margin-1898.65%
EBITDA Margin2.48%
Profit Margin-6.37%
ROE-11.40%
ROA-3.69%
Growth
Revenue Growth-56.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF4.93M USD
CapEx (TTM)182.31K USD
FCF Margin-0.43%
FCF Yield-0.19%
Net Debt851.78K USD
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.41
Current Ratio0.96
Quick Ratio0.49
Book Value/Sh1.16 USD
Cash/Share0.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateAug 3, 2026
Pay DateJul 31, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.14.98M
Float8.70M
Insiders41.60%
Institutions16.56%
Short Interest
Short Ratio4.0d
Short % Float2.88%
Short % Out.1.68%
Shares Short252.45K
Short (prev mo.)326.21K
Technical
SMA 507.411 (-10.2%)
SMA 2005.317 (+25.2%)
Beta0.04
S&P 52W Chg16.45%
Avg Vol (30d)45.54K
Avg Vol (10d)39.66K
Technical Indicators
RSI (14)43.2
MACD-0.0018
MACD Signal0.0701
MACD Hist.-0.0719
BB Upper8.410 USD
BB Middle7.268 USD
BB Lower6.125 USD
BB Width31.44%
ATR (14)0.4973 USD
Vol Ratio (20d)0.65x